U.S. drug reviewers released a report on Tuesday indicating that the use of some contrast agents is riskier than others. According to the report, people who use these drugs have a better chance of contracting certain skin diseases. 

These drugs include GE Healthcare's Omniscan, Bayer AG's Magnevist and Covidien's Optimark. The Food and Drug Administration linked these drugs to such diseases as nephrogenic systemic fibrosis. 

If you or anyone you know has used these contrast agents, contact the gadolinium lawyers of Williams Kherkher at 800-761-3187. 

Optimark will undergo a voluntarily label change to notify users of the risks associated with the product. According to MSN's Market Report, Covidien announced that it will contraindicate the Optimark gadovesetamide injection. 

The injection is used as a gadolinium-based contrast agent for magnetic resonance imaging procedures. While some label changes are voluntary, gadolinium-based contrast agents have been associated with mandatory label changes in the past to inform patients about the risks. 

If you or anyone you know has suffered negative side effects as a result of being injected with a gadolinium-based contrast agent, contact the NSF and NFD lawyers of Williams Kherkher at 800-761-3187.

When undergoing an MRI, people with kidney problems should exercise care. While not all MRI scans are dangerous for people with kidney problems, MRIs with some contrast agents may pose a serious risk. 

Gadolinium contrast agents pose a risk because they increase the chance of contracting nephrogenic systemic fibrosis (NSF). NSF causes the thickening of the skin, organs, and other tisues. 

If you have kidney problems and suffered serious side effects from a gadolinium-based contrast agent, contact the NSF lawyers of Williams Kherkher at 800-761-3187.

The FDA has released its list of drugs that are being reviewed for safety problems. These drugs include gadolinium-based contrast agents, which are used during magnetic resonance imaging. 

The FDA is investigating these drugs for potential links to anaphylaxis hypersensitivity. The drugs have already been linked to Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy. 

If you or anyone you know has received a gadolinium-based contrast agent, contact the NSF and NFD lawyers of Williams Kherkher at 800-761-3187.

Gadolinium is one of many metals being used in high-tech devices. These types of metals, which are heavily mined in China, are commonly known as rare-earth metals. 

Other types of rare-earth metals include cerium, samarium, europium, erbium, and thulium, among others. These metals are often used in products like magnets for cars, wind turbines, computer monitors, and televisions. 

Although these metals have helped engineer many technological breakthroughs, some can have harmful side effects. Among those is gadolinium, which is used as a contrast agent in MRIs and may lead to Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy (NFD).

If you have been exposed to gadolinium, contact the NSF and NSF lawyers of Williams and Kherkher at 800-761-3187.

Although some doctors and other health officials doubt the link between Nephrogenic Systemic Firbrosis (NSF) and MRI testing with gadolinium, many doctos believe the link exists and have even gone as far to state that it may go beyond causing kidney failure. 

Many doctors main worry is that people who have received MRIs could be developing NSF without knowing it. In such cases, the damage caused by NSF could be life-threatening, affecting organs other than the kidneys. 

Some doctors suggest that any patient who has received gadolinium see their local doctor for the appropriate tests. 

If you or anyone you know has questions about NSF, contact the NSF and NSD lawyers of Williams and Kherkher at 800-761-3187.

The Federal Drug Administration (FDA) has approved gadolinium for use as a contrast agent in Magnetic Resonance Imaging (MRI). As a contrast agent, gadolinium allows MRIs to generate a clearer picture of the body’s organs and tissues.

Although MRIs can be performed without the contrast agent, the use of contrast agents allows doctors to better diagnose patients. Currently, gadolinium is the only FDA-approved contrast agent.

Gadolinium has been cited as the potential cause for patients contracting Nephrogenic Systemic Fibrosis (NSF), when the patient underwent an MRI that used gadolinium. Currently, the FDA has not established an official causal link between gadolinium and NSF, but is currently doing research to evaluate whether a causal link exists.

If you or anyone you know suffers from NSF and underwent an MRI with the gadolinium-contrast agent, please contact the NSF lawyers of Williams Kherkher at 800-761-3187.